These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15960555)

  • 1. Pharmacoeconomic evaluation of antidepressants : a critical appraisal of methods.
    Iqbal SU; Prashker M
    Pharmacoeconomics; 2005; 23(6):595-606. PubMed ID: 15960555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic issues in the treatment of depression.
    Saklad SR
    Pharmacotherapy; 1995; 15(6 Pt 2):76S-83S. PubMed ID: 8587854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical review of selected pharmacoeconomic analyses of antidepressant therapy.
    Conner TM; Crismon ML; Still DJ
    Ann Pharmacother; 1999 Mar; 33(3):364-72. PubMed ID: 10200863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic evaluation of antidepressant therapies.
    Sarnes MW; Frankum LE
    Manag Care; 2004 Jun; 13(6 Suppl Depression):34-41. PubMed ID: 15293769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of St John's Wort for the treatment of depression: the economic perspective.
    Solomon D; Ford E; Adams J; Graves N
    Aust N Z J Psychiatry; 2011 Feb; 45(2):123-30. PubMed ID: 20977305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.
    Henry JA; Rivas CA
    Pharmacoeconomics; 1997 Jun; 11(6):515-37. PubMed ID: 10168093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness measures of major depressive disorder in pharmacoeconomic evaluations.
    Casciano R
    Manag Care Interface; 2003; Suppl B():14-5. PubMed ID: 12647608
    [No Abstract]   [Full Text] [Related]  

  • 10. Who bears the costs of antidepressants in Australia?
    Gorham PN
    Med J Aust; 1995 Feb; 162(3):162-3; author reply 164. PubMed ID: 7854234
    [No Abstract]   [Full Text] [Related]  

  • 11. Who bears the costs of antidepressants in Australia?
    Haski RR; Grainger D
    Med J Aust; 1995 Feb; 162(3):164. PubMed ID: 7854236
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The added costs of depression to medical care.
    Franco K; Tamburino M; Campbell N; Zrull J; Evans C; Bronson D
    Pharmacoeconomics; 1995 Apr; 7(4):284-91. PubMed ID: 10155318
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder.
    Burke MJ; Silkey B; Preskorn SH
    J Clin Psychiatry; 1994 Sep; 55 Suppl A():42-52; discussion 53-4, 98-100. PubMed ID: 7961542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling cost-effectiveness issues in the treatment of clinical depression.
    Sorensen J; Kind P
    IMA J Math Appl Med Biol; 1995; 12(3-4):369-85. PubMed ID: 8919571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
    Revicki DA; Frank L
    Pharmacoeconomics; 1999 May; 15(5):423-34. PubMed ID: 10537960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
    Lenox-Smith A; Conway P; Knight C
    Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using pharmacoeconomic data to compare antidepressant therapies.
    Manag Care; 2001 Aug; 10(8 Suppl):14-5; discussion 18-22. PubMed ID: 11729433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.